Radiation Sparing Reduced Intensity Conditioning for Allogeneic Cell Transplantation in Patients with Dyskeratosis Congenita Comparable to Standard of Care: A Phase III Single Institution Trial

Marketa Dimitrov(University of Minnesota Medical Center), Christen L. Ebens(University of Minnesota), Svatava Merkle(Cincinnati Children's Hospital Medical Center), Shernan G. Holtan(University of Minnesota), Gregory M. Vercellotti(University of Minnesota Medical Center), Jakub Tolar(University of Minnesota System)
Blood
November 15, 2022
10.1182/blood-2022-165290
Cited by 0

Related Papers

Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial
|The Lancet|2020|1k
Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins
|Blood|2012|743
Carbon Monoxide Generated by Heme Oxygenase-1 Suppresses the Rejection of Mouse-to-Rat Cardiac Transplants
|The Journal of Immunology|2001|462
3D Printed Functional and Biological Materials on Moving Freeform Surfaces
|Advanced Materials|2018|242
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Dyskeratosis Congenita
|Biology of Blood and Marrow Transplantation|2013|130